AHPBA IRE Registry
Pancreatic Cancer
Post-Market RegistryActive
Key Facts
About AngioDynamics
AngioDynamics is a publicly traded medical device company with a mission to improve patient lives by providing innovative, minimally invasive tools for treating peripheral vascular disease and cancer. The company has strategically evolved from a broad vascular access provider into a focused innovator, building a diversified technology portfolio through R&D and acquisitions. Its current strategy centers on commercializing and expanding the clinical evidence for its three core platforms—Auryon, AlphaVac, and NanoKnife—while navigating a competitive landscape and managing the financial and operational challenges of a mid-cap device maker.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |
| Electron IORT | Intraop Medical | Approved |